iOnctura is a clinical-stage biotechnology company that specializes in developing treatments for cancer.
iOnctura has raised $85.7M in total funding. The most recent round was Series B. The last funding was announced in June 2024.
iOnctura's investors include Schroders Capital, Inkef, European Innovation Council, 3B Future Health Fund, VI Partners.
iOnctura is headquartered in Genive, Switzerland.
iOnctura is a clinical-stage biotechnology company that specializes in developing treatments for cancer.
iOnctura is at the Series B stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"iOnctura — Funding & Investors." VCBacked, June 20, 2024, https://www.vcbacked.co/company/ionctura. Accessed July 20, 2026.
VCBacked. (2024). iOnctura — Funding & Investors. Retrieved July 20, 2026, from https://www.vcbacked.co/company/ionctura
{{cite web |title=iOnctura — Funding & Investors |url=https://www.vcbacked.co/company/ionctura |website=VCBacked |access-date=July 20, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated